Conatus Pharmaceuticals Inc
Analysts’ Ratings for Enanta Pharmaceuticals and Peers in April
Of the four analysts covering Enanta Pharmaceuticals, one analyst gave the stock a “buy” rating and three analysts gave it a “hold.”
Analysts’ Ratings for FibroGen and Its Peers in April 2018
Of the seven analysts covering FibroGen in April, five have given the stock “strong buy” ratings, while two have given it “hold” ratings.
Which Gilead Sciences Portfolio Could Give a Long-Term Boost
NASH is a chronic disease related to steatosis wherein fat accumulates in the liver and can lead to inflammation, progressive fibrosis, and cirrhosis.